Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00525447
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- Conditions
- Prostate Cancer
- Interventions
- Dietary Supplement: calcitriolDrug: dexamethasoneGenetic: protein expression analysisOther: laboratory biomarker analysis
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00524589
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
- Conditions
- Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
- Interventions
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00522392
- Locations
- 🇺🇸
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States
🇺🇸Illinois Oncology Research Association CCOP, Peoria, Illinois, United States
🇺🇸Saint Francis Hospital and Health Centers, Beech Grove, Indiana, United States
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
- Conditions
- Primary Systemic AmyloidosisLight Chain Deposition Disease
- Interventions
- Drug: bortezomibDrug: dexamethasoneDrug: melphalanGenetic: microarray analysisOther: flow cytometryOther: laboratory biomarker analysisProcedure: quality-of-life assessment
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT00520767
- Locations
- 🇺🇸
Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
🇺🇸Boston University Cancer Research Center, Boston, Massachusetts, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2007-08-14
- Lead Sponsor
- Ziv Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00516009
- Locations
- 🇮🇱
Neurology Unit - Ziv Mc, Safed, Israel
Papillary Serous Carcinoma of the Endometrium
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00515073
- Locations
- 🇺🇸
M. D. Anderson Cancer Center - Orlando, Orlando, Florida, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
- Conditions
- Choroidal NeovascularizationAge-Related Maculopathy
- Interventions
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 243
- Registration Number
- NCT00511706
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
- Conditions
- Lymphoma, Follicular
- Interventions
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Duke University
- Target Recruit Count
- 14
- Registration Number
- NCT00510887
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2011-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00507858
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT00507416
- Locations
- 🇺🇸
Hematology Oncology Consultants Inc., Columbus, Ohio, United States
🇺🇸S. Florida Oncology/ Hematology, West Palm Beach, Florida, United States
🇺🇸Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.